Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDR

Muluwork Getahun, Gobena Ameni, Hilina Mollalign, Getu Diriba, Dereje Beyene

Abstract read

In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muluwork GetahunEthiopian Public Health Institute, Addis Ababa, Ethiopia.ORCID 0000-0003-3407-983X

Gobena AmeniAklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.

Hilina MollalignEthiopian Public Health Institute, Addis Ababa, Ethiopia.

Getu DiribaEthiopian Public Health Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-0166-682X

Dereje BeyeneDepartment of Microbial, Cellular and Molecular Biology, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026

$3.4M

FIC NIH HHS D43 TW009127

6 · The paper itself

Abstract

Resistance-conferring mutations in IMPORTANCE: Drug resistance mutations vary by location, effectiveness of the national control programs, and the diagnostic methods employed. Rapid molecular diagnostic tests are the primary methods used to detect drug-resistant tuberculosis. Comprehensive resistance mutation profiles are often lacking in low- and middle-income countries. The goal of this study was to assess the patterns and frequencies of mutations conferring first-line drug resistance in Ethiopia using isolates collected from the drug resistance survey. The isolates were obtained before the implementation of rapid molecular tests. The findings will enhance our understanding of the patterns and frequencies of mutations that confer resistance, which is crucial for developing a comprehensive catalog of mutations.

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialIsoniazidMycobacterium tuberculosisRifampinTuberculosis, Multidrug-ResistantAdolescentAdultBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesEthiopiaFemaleGenotypeHumansMaleAntitubercular AgentsBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesIsoniazidRifampindrug resistance mutationsdrug-resistant surveyinferred mutationline probe assaymolecular diagnosticsMycobacterium tuberculosistreatment history

Identifiers

PMID41718507

DOI10.1128/spectrum.01454-25

PMCPMC13055254

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.